Translational Medicine Team Lead, Oncology
Oscar Puig is Translational Medicine Team Lead, Oncology at Bristol-Myers Squibb. He was formerly the Chief Scientific Officer at Phosphorus, a genetic diagnostic company founded in 2016 that develops diagnostics for complex genetic diseases and software for clinical data management and analysis. Prior to that, he was a Biomarker Leader in Oncology at the Roche Innovation Center in New York. He earned his Ph.D. at the University of Valencia, Spain, and carried out postdoctoral research at the European Molecular Biology Laboratory, in Heidelberg, Germany, and in the lab of Bob Tjian, at UC Berkeley, CA. Before joining Roche in 2012, he worked at Merck and at the University of Helsinki, where he is a docent. Dr Puig has over 40 publications in peer-reviewed journals.
The Journal of Precision Medicine
Tom is Senior Editor of the Journal of Precision Medicine. Tom was previously Director of Strategic Alliances at PlanetConnect and spent over 13 years with Merck & Co., including over 30 years in biotechnology and technology. He received his PhD in Electrical Engineering and Science at the University of Pennsylvania. He has authored or co-authored peer-reviewed papers in fields ranging from circuit design to gene profiling technologies.
Chief Scientific Officer and Co-Founder
Regional Pharma Consulting
John S. Mudgett, Ph.D. is Chief Scientific Officer and Co-Founder of Regional Pharma Consulting. John was Vice President, Genesis Drug Discovery Services at the Genesis Biotechnology Group. Dr. Mudgett, was owner of JsM BioScience, LLC, providing science and business development consultation services to Biotech, CRO, and Scientific Conference business. His services included opportunity assessment, and science and business evaluation for client penetration into the Pharma and Biotech customer base. Prior to that, John was External Lead – Pharmacology, Merck Research Laboratories, a position with increasing responsibilities he held for 12 years. At Merck, he brought extensive experience in the execution of scientific, business development, managerial, financial, Lean Sigma, and IT delivery for translational BioPharma support of a diverse portfolio of programs in the global CRO arena. John was a founding member of the GEM department, tasked with taking an entrepreneurial approach to partnering with internal research to create an inception-to-impact return on investment with external providers in the US and global arenas. John was responsible for domestic and global scientific and business development, CRO alliance management, external project management, internal-external collaborations, and delivery of pipeline supporting data for program advancement. Awarded the Merck Research Laboratories Customer Focus Award, he was recognized for bringing value and experience to both internal and external customer needs and business solutions. Dr. Mudgett holds Doctorate and Masters degrees from The Pennsylvania State University and a B.S. with high distinction from The University of Maine. He has completed postdoctoral training at Los Alamos National Laboratory, where he was awarded the Alexander Hollaender Postdoctoral Fellowship Award. He is a Six Sigma certified greenbelt, and led an effort that returned $30 million to Merck in efficiencies, while increasing the scientific deliverables. John serves as a Scientific Advisor to the Panel of Scientific Consultants for the International Mouse Phenotyping Consortium (IMPC), funded by the NIH Common Fund. He also serves as a member of the Scientific Advisory Board for PHENOMIN, the French National Infrastructure for Mouse Phenogenomics. In addition, John is a member of the BioPharma Research Council committee for helping to organize speakers and conference sessions for upcoming events. John and his wife Kristine are actively involved in Preschool Advantage, a charitable organization serving children and families of need in obtaining quality preschool access and tuition. In addition, John is an avid wood craftsman, making custom wood-crafted products.
PlanetConnect & Board of Directors, BioPharma Research Council
Ronnye co-founded PlanetConnect in 1995 and is the company CEO. She is also Co-founder and member of the Board of Directors of the non-profit, BioPharma Research Council (BRC). She leads teams creating customized internal and external meetings and trade shows for Pharmaceuticals, Telecommunications and AgBio organizations. Past working lives have been spent in labs in Johnson & Johnson, Rutgers Medical School, Sidney Farber Cancer Institute, Arthur D. Little, and Ortho Diagnostics and in libraries and marketing at AT&T and Lucent Bell Laboratories.